Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries

BMC Cardiovasc Disord. 2024 Jul 2;24(1):332. doi: 10.1186/s12872-024-04011-w.

Abstract

The anticancer drug of tyrosine kinase-inhibitors (TKIs) has significantly improved the prognosis of patients with specific leukemia but has also increased the risk of organ adverse reactions. Herein, we present a case of a patient diagnosed with myeloproliferative neoplasms who experienced recurrent chest pain after receiving treatment with Olverembatinib. Electrocardiography and coronary angiography confirmed the diagnosis of myocardial infarction with non-obstructive coronary arteries. This case serves as a reminder for clinicians to pay more attention and actively prevent the cardiac adverse reactions of TKIs when using such medications.

Keywords: MINOCA; Olverembatinib; TKI.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Cardiotoxicity
  • Coronary Angiography*
  • Electrocardiography
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / chemically induced
  • Myocardial Infarction / diagnosis
  • Protein Kinase Inhibitors* / adverse effects
  • Treatment Outcome

Substances

  • Protein Kinase Inhibitors
  • Antineoplastic Agents